geno 1

Is it very common to be undetectable after 4 weeks with geno 1a?  mine dropped from like 20million to 2 million so will be doing 48 weeks

[Idyllic]

UND in week 4 (& remaining so in week 12) is called eRVR (Extended Rapid Virological Response)

The Inviek site says in the Advance trial says:

The majority of treatment-naïve patients (58%) and prior relapsers (78% and 76% in the Phase 2 and REALIZE trials, respectively) achieved eRVR (undetectable HCV RNA at Weeks 4 and 12). eRVR is used to determine treatment duration in appropriate patients.

So 42% do not.

In the Illuminate trial 65% achieved eRVR
_____________________


http://www.incivek.com/hcp/extended-rapid-virologic-response-ervr

Hang in there!
You will slay this beast!

[hrsepwrguy]

I think she is on victrelis

[hrsepwrguy]

In addition, consideration should be given to treating previously untreated patients who are poorly interferon responsive (as determined at TW4) with 4 weeks peginterferon alfa and ribavirin followed by 44 weeks of VICTRELIS 800 mg orally three times daily (every 7 to 9 hours) in combination with peginterferon alfa and ribavirin in order to maximize rates of SVR [see Clinical Studies (14)]

Previously Untreated Subjects In previously untreated subjects evaluated in SPRINT-2, interferon-responsiveness (defined as greater than or equal to 1-log10 decline in viral load at TW4) was predictive of SVR. VICTRELIS-treated subjects who demonstrated interferon responsiveness at TW4 achieved SVR rates of 81% (203/252) in VICTRELIS-RGT arm and 79% (200/254) in VICTRELIS-PR48 arm, compared to 52% (134/260) in subjects treated with PegIntron/REBETOL.  VICTRELIS-treated subjects who demonstrated poor interferon responsiveness (defined as less than 1-log10 decline in viral load at TW4), achieved SVR rates of 28% (27/97) in VICTRELIS-RGT arm and 38% (36/95) in VICTRELIS-PR48 arm, compared to 4% (3/83) in subjects treated with PegIntron/REBETOL.  Subjects with less than a 0.5-log10 decline in viral load at TW4 achieved SVR rates of 28% (13/47) in VICTRELIS-RGT arm and 30% (11/37) in VICTRELIS-PR48 arm, compared to 0% (0/25) in subjects treated with PegIntron/REBETOL. Subjects with less than a 0.5-log10 decline in viral load at TW4 with peginterferon alfa plus ribavirin therapy alone are predicted to have a null response (less than 2-log10 viral load decline at TW12) to peginterferon alfa and ribavirin.

You had a 1 log drop after the 4 week lead in

[Idyllic]

Oh sorry I get the 48 weeks of treatment with barely a one log drop by the four week point.

I think the point is that in the trials a person did not have to be UND at week 4 only a 1 log drop to still have the better odds

_________________--
The very last sentence in this article says. "Highest SVR rates found in patients treated with boceprevir-based regimen who experienced ≥ 1 log10 decline in HCV RNA after 4-week pegIFN/RBV lead-in, regardless of IL28B genotype.

http://www.clinicaloptions.com/Hepatitis/Conference%20Coverage/Berlin%202011/From%20Podium%20to%20Practice/Capsules/12.aspx?lg=print

_____________________

Hang in there!!!!!